US 12,351,837 B2
Supernegatively charged proteins and uses thereof
Yongjoo Kim, Cambridge, MA (US); David R. Liu, Cambridge, MA (US); and Kevin Tianmeng Zhao, Cambridge, MA (US)
Assigned to The Broad Institute, Inc., Cambridge, MA (US); and President and Fellows of Harvard College, Cambridge, MA (US)
Appl. No. 17/425,261
Filed by The Broad Institute, Inc., Cambridge, MA (US); and President and Fellows of Harvard College, Cambridge, MA (US)
PCT Filed Jan. 23, 2020, PCT No. PCT/US2020/014789
§ 371(c)(1), (2) Date Jul. 22, 2021,
PCT Pub. No. WO2020/154500, PCT Pub. Date Jul. 30, 2020.
Claims priority of provisional application 62/795,912, filed on Jan. 23, 2019.
Prior Publication US 2023/0002745 A1, Jan. 5, 2023
Int. Cl. C07K 14/575 (2006.01); A61K 9/127 (2025.01); A61K 9/51 (2006.01); A61K 38/00 (2006.01); C07K 14/47 (2006.01); C12N 9/22 (2006.01); C12N 9/78 (2006.01)
CPC C12N 9/22 (2013.01) [A61K 9/5123 (2013.01); C07K 14/4702 (2013.01); C07K 14/4728 (2013.01); C07K 14/57581 (2013.01); C12N 9/78 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01)] 19 Claims
 
1. A composition comprising a cationic lipid or a cationic polymer and a supernegatively charged protein associated with an effector protein, wherein the supernegatively charged protein is a prothymosin alpha (ProTα) fragment comprising an amino acid sequence of SEQ ID NO: 2 or 3.